Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

ard-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contact

David A. Ramsay Karen Sparks / Joleen Schultz

Chief Financial Officer Mentus

(858) 704-8260 (858) 455-5500, x275/x215

dramsay@halozyme.com karen@mentus.com

jschultz@mentus.com

HALOZYME THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 AND 2006

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

REVENUES:

Product sales $98,170 $115,206 $639,590 $670,625

Revenue under

collaborative

agreements 1,239,739 311,121 3,159,931 311,121

Total Revenues 1,337,909 426,327 3,799,521 981,746

OPERATING EXPENSES:

Cost of sales 29,229 41,399 240,429
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Topical BioMedics, Inc., is ... pain end their suffering, restoring hope an quality of ... is only possible because of the innovative cellular biomedicines ... technology a reality. , The company was founded ... Lou Paradise (president, chief of research, and Topricin inventor), ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 ... announced that it has entered into a collaboration ... UHN,s Centre for Molecular Design and Preformulations (CMDP) ... The goal of the project is to increase ... proprietary buccal insulin spray product, thereby reducing the ...
(Date:9/22/2014)... Norway (PRWEB) September 22, 2014 ... new parcel and pallet measuring device CNS110 ... eliminates manual data entry, offering greater ease and ... savings that result can significantly enhance productivity—an important ... industries where processing volume equals profits. , ...
(Date:9/21/2014)... 21, 2014 Chemical Sciences play ... such as clean air and safe water, healthy ... products. Chemists, environmentalists, food scientists, educators, and scientists ... in the field of Chemistry for the national ... is one of the fastest emerging Sciences, accelerating ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4ScanTape™ Handheld Dimensioner Increases Processing Volume 2Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Results for Sponsoring BrandsCINCINNATI, May 12 ... of physician office-based patient-education programs, announces another record ... climate, the company continued to experience double-digit growth, ... primary care programs (a digital screen waiting room ...
... May 12 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... BioMarin, will present a company update at the Deutsche Bank ... 19, 2009 at 1:55 p.m. ET. Interested parties may ... the investor section of the BioMarin website, www.BMRN.com ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
Cached Biology Technology:Healthy Advice Networks Achieves Strong Growth Despite Challenging Economy 2BioMarin to Present at the Deutsche Bank Health Care Conference 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3
(Date:9/22/2014)... 2014) Additive manufacturing (AM), or 3D printing, ... of complex-shaped metal components strong enough for structural ... and distortions, as well as quality standards to ... with the technology. Engineers at the University of ... develop enhanced modeling and simulation (M&S) technology and ...
(Date:9/22/2014)... SHELTON, Conn. , Sept. 22, 2014 ... authentication company focused on the growing mobile commerce market, ... to NASDAQ and the recent funding. ... recently completed an essential round of funding and joined ... as well as expand its other biometric and authentication ...
(Date:9/21/2014)... are set to rise again in 2014 - reaching a ... cent projected rise in burning fossil fuels is revealed by ... by researchers at the Tyndall Centre for Climate Change Research ... Engineering, Mathematics and Physical Sciences at the University of Exeter. ... where world leaders will seek to catalyse action on climate ...
Breaking Biology News(10 mins):Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3
... international research consortium has sequenced the genome of the ... Dec. 26 advance online edition of the journal ... possibilities for breeding tastier, hardier varieties of the berry ... the strawberry parts list," said the consortium,s leader Kevin ...
... COLLEGE PARK, Md. The latest success of Martek ... a decade ago in a plain, brick building on ... and early-stage nurturing from the university,s Maryland Technology Enterprise ... into a major international business. On December ...
... University of Arizona researchers may have found a way ... doses without harming healthy body cells. If successful, ... effective to destroy cancer cells and alleviate the harmful ... The invention by Marek Romanowski, an associate professor of ...
Cached Biology News:Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Tech firm joins the 'billion dollar club' -- with university help 2Tech firm joins the 'billion dollar club' -- with university help 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 2Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 4
... kit I provides reagents and a protein standard ... reducing agents and detergents. The RC DC protein ... reagents and standards sufficient for 500 standard assays: ... reagent II, 250 ml alkaline copper tartrate solution, ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
... The Eclipse is a state-of-the-art separation ... Fractionation (AFFF) technique. The Eclipse integrates easily ... DAWN, miniDAWN Tristar, as well as the ... size and molar mass distributions of the ...
... reagent kit for determining the absolute count ... samples, mobilized peripheral blood samples, and leukapheresis ... total nucleated cell count and a total ... designed for use in the BD Procount ...
Biology Products: